Investigational agents for Crohn's disease

Expert Opinion on Investigational Drugs

Volumn 19, Issue 10, 2010, Pages 1147-1159

  Cottone, Mario ^a   Orlando, Ambrogio ^a   Renna, Sara ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

biologic; CD; Crohn's disease; immunity; interleukin; therapy

Indexed keywords

ADALIMUMAB; ALICAFORSEN; AZATHIOPRINE; BASILIXIMAB; BETA1A INTERFERON; CERTOLIZUMAB PEGOL; DACLIZUMAB; DORAMAPIMOD; EVEROLIMUS; FONTOLIZUMAB; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; NATALIZUMAB; PLACEBO; PREDNISOLONE; PROBIOTIC AGENT; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; SEMAPIMOD; TOCILIZUMAB; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB;

ADAPTIVE IMMUNITY; BACTERIAL FLORA; BACTEROIDES; CELLULAR IMMUNITY; CLINICAL PRACTICE; CLINICAL TRIAL; CROHN DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HELPER CELL; HUMAN; INNATE IMMUNITY; LACTOCOCCUS LACTIS; NONVIRAL GENE DELIVERY SYSTEM; REMISSION; REVIEW; TREATMENT FAILURE; ULCERATIVE COLITIS;

ADAPTIVE IMMUNITY; ANTIBODIES, MONOCLONAL; CELL ADHESION MOLECULES; CROHN DISEASE; CYTOKINES; DRUGS, INVESTIGATIONAL; GASTROINTESTINAL AGENTS; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION;

EID: 77956575279     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.510513     Document Type: Review

References (88)

1. Peyrin-Biroulet L, Deltenre P, De Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-653
2. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009;136:1182-1197
3. Tine F, Rossi F, Sferrazza A, et al. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease. Aliment Pharmacol Ther 2008;27:1210-1223
4. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-2078
5. Ambrose NS, Johnson M, Burdon DW, et al. Incidence of pathogenic bacteria from mesenteric lymph nodes and ileal serosa during Crohn's disease surgery. Br J Surg 1984;71:623-625
6. Li Y, Karlin A, Loike JD, et al. Determination of the critical concentration of neutrophils required to block bacterial growth in tissues. J Exp Med 2004;200:613-622
7. Clavel T, Haller D. Bacteria and host derived mechanisms to control intestinal epithelial cells homeostasis: implications for chronic inflammation. Inflamm Bowel Dis 2007;13:1419-1423
8. Liu Y, Van Kruiningen HJ, West AB, et al. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995;108:1396-1404
9. Meconi S, Vercellone A, Levillain F, et al. Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. Cell Microbiol 2007;9:1252-1261
10. Rhodes JM. The role of Escherichia coli in inflammatory bowel disease. Gut 2007;56:610-612
11. Ng SC, Hart AL, Kamm MA, et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009;15:300-310
12. Madsen KL, Doyle JS, Jewell LD, et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 1999;116:1107-1114
13. Mileti E, Matteoli G, Iliev ID, et al. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 2009;4:e7056
14. Matsumoto S, Hara T, Nagaoka M, et al. A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. Immunology 2009;128:e170-80
15. Feighery LM, Smith P, O'Mahony L, et al. Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease. Dig Dis Sci 2008;53:2495-2506
16. Sood A, Midha V, Makaria GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild to moderate active ulcerative colitis. Clin Gastroenterol Hepatol 2009;11:1202-1209
17. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-1209
18. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-309
19. Schultz M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1012-1018
20. Rahimi R, Nifkar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008;53:2524-2531
21. Marks DJB, Harbord M, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006;367:668-678
22. Segal AW, Loewi G. Neutrophil dysfunction in Crohn's disease. Lancet 1976;2(7979):219-221
23. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603
24. Koslowski MJ, Beisner J, Stange EF, et al. Innate antimicrobial host defense in small intestinal Crohn's disease. Int J Med Microbiol 2010;300:34-40
25. Lala S, Ogura Y, Osborne C, et al. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003;125:47-57
26. Ogura Y, Lala S, Xin W, et al. Expression of NOD2 in paneth cells: a possible link to Crohn's ileitis. Gut 2003;52:1591-1597
27. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-832
28. Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009;41:1330-1334
29. Korzenick JR, Dieckgraefe BK, Valentine JF, et al. Salmograstin for active Crohn's disease. N Engl J Med 2005;352:2193-2201
30. Feagan BG, Anderson F, Radford-Smith GL, et al. Efficacy and safety of Salmograstin in moderate to severe Crohn's disease: results of NOVEL 4 phase multicenter study. Gastroenterology 2007;132(Suppl 2):A 103
31. Valentine JF, Fedorak RN, Feagan B, et al. Steroid sparing properties of sarmograstin in patients with corticosteroid dependent Crohn's disease: a randomized double blind placebo controlled phase 3 study. Gut 2009;58:1354-1362
32. Takazoe M, Matsui T, Motoya S, et al. Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. J Gastroenterol 2009;44:535-543
33. Mosmann TR, Kobie JJ, Lee FE, et al. T helper cytokine patterns: defined subsets, random expression, and external modulation. Immunol Res 2009. [Epub ahead of print]
34. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357
35. Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm bowel Dis 2007;13:1419-1423
36. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 2009;58:1152-1167
37. Van Deventer SJH, Elson C, Fedorak R. Multiple doses of intravenous interleukin 10 in steroid refractory Crohn's disease. Gastroenterology 1997;113:383-389
38. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 in the prevention of postoperative recurrence. Gut 2001;49:42-46
39. Steider L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactoccoccvus lactis secreting interleukin-10. Science 2000;289:1352-1355
40. Braat H, Rottiers P, Hommes DW, et al. A phase 1 trial with transgenic bacteria expressing interleukin 10 in Crohn's disease. Clin Gastroenterol Hepatol 2006;4:754-759
41. Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin-11 in patients with active Crohn's disease. Gastroenterology 1999;117:58-64
42. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002;16:399-406
43. Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized double blind controlled trial of subcuteaneous recombinant human interleukin 11 versus prednisolone in active CD. Am J Gastroenterol 2006;101:793-797
44. Ito H, Takazoe, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-996
45. Guan Q, Ma Y, Hillman CL, et al. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 2009;27:7096-7104
46. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-2079
47. Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006;12:558-565
48. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 2008;135:1130-1141
49. Reinisch W, Panes J, Lemann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008;103:2284-2292
50. Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006;55:1138-1144
51. Hommes DW, Mikhajlova TL, Stoinov S, et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 2006;55:1131-1137
52. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010;16(2):233-242
53. Pena-Rossi C, Schreiber S, Golubovic G, et al. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-1a in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:758-767
54. Abbas A, Lichtman A, Pillai S. Cellular and molecular immunolology. 6th edition. Elsevier; 2007
55. Liu Z, Colpaert S, D'Haens GR, et al. Hyperexpression of CD40 ligand in inflammatory bowel disease and its role in pathogenic cytokine production. J Immunol 1999;163:4049-4057
56. Kasran A, Boon A, Wortel H. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005;22:111-1122
57. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009;(4):CD007277
58. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001;121:268-274
59. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32
60. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. N Engl J Med 2005;353:1912-1925
61. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-1683
62. Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007;13:2-11
63. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008;6:1370-1377
64. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-1142
65. Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002;16:1761-1770
66. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002;51:30-36
67. Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007;5:215-220
68. Keshav S, Wolf D, Katz S, et al. CCX282-B, an orally active inhibitor of chemokine receptor CCR9, in a randomized, double-blind, placebo-controlled phase 2 study in moderate to severe Crohn's disease. Gut 2006;A22:OP-G-93
69. Hommes D, Van de blink B, Plasse T, et al. Inhibition of stress activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002;122:7-14
70. Schreiber S, Feagan B, D'Haens G, et al. Oral p38 mitogen activated protein kinase inibition with BIRB 796 for active Crohn's disease:a randomized double blind placebo controlled trial. Clin Gastroenterol Hepatol 2006;4:325-334
71. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-TNFalpha antibody, administered intravenously in patients with active rheumatoid arthritis: 48-Week efficacy and safety results of a phase 3, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62(4):917-928
72. Mascheretti S, Schreiber S. The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease. Pharmacogenomics 2004;5:479-486
73. Su C, Lichtenstein GR, Krok K, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257-1269
74. Targan SR, Hanauer SB, van Deventer S, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-1035
75. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-1405
76. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-333
77. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-1239
78. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18.
79. Erratum in: Gastroenterology 2005;129:1808
80. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-238
81. Winter TA, Wright J, Ghosh S, et al. Intravenous CDP870, a PEGylated Fab́ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol Ther 2004;20:1337-1346
82. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-1549
83. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-885
84. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009;136:441-450
85. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56:1232-1239
86. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65
87. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-250
88. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-769